← Back to Screener
PepGen Inc. Common Stock (PEPG)
Price$1.73
Favorite Metrics
Price vs S&P 500 (26W)-72.69%
Price vs S&P 500 (4W)-73.32%
Market Capitalization$117.50M
All Metrics
Book Value / Share (Quarterly)$2.14
P/TBV (Annual)0.59x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.19
Price vs S&P 500 (YTD)-78.02%
EPS (TTM)$-2.42
10-Day Avg Trading Volume1.51M
EPS Excl Extra (TTM)$-2.42
EPS (Annual)$-2.12
ROI (Annual)-60.81%
Cash / Share (Quarterly)$2.16
ROA (Last FY)-51.55%
EBITD / Share (TTM)$-2.18
ROE (5Y Avg)-53.63%
Cash Flow / Share (Annual)$-1.19
P/B Ratio0.80x
P/B Ratio (Quarterly)3.04x
Net Income / Employee (Annual)$-2
ROA (TTM)-60.41%
EPS Incl Extra (Annual)$-2.12
Current Ratio (Annual)11.94x
Quick Ratio (Quarterly)11.74x
3-Month Avg Trading Volume1.14M
52-Week Price Return38.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.29
52-Week High$7.80
EPS Excl Extra (Annual)$-2.12
CapEx CAGR (5Y)92.45%
26-Week Price Return-63.94%
Quick Ratio (Annual)11.74x
13-Week Price Return-66.99%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.94x
Enterprise Value$56.982
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.16
3-Month Return Std Dev152.86%
Net Income / Employee (TTM)$-2
ROE (Last FY)-60.81%
EPS Basic Excl Extra (Annual)$-2.12
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.42
ROI (TTM)-75.73%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.58
Price vs S&P 500 (52W)3.12%
Year-to-Date Return-73.89%
5-Day Price Return0.59%
EPS Normalized (Annual)$-2.12
ROA (5Y Avg)-43.39%
Month-to-Date Return-3.95%
Cash Flow / Share (TTM)$-3.07
EBITD / Share (Annual)$-2.18
ROI (5Y Avg)-53.63%
EPS Basic Excl Extra (TTM)$-2.42
P/TBV (Quarterly)0.85x
P/B Ratio (Annual)3.04x
Book Value / Share (Annual)$2.14
Price vs S&P 500 (13W)-69.86%
Beta2.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-75.73%
52-Week Low$1.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PEPGPepGen Inc. Common Stock | — | — | — | — | $1.73 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The EDO platform improves tissue penetration and cellular uptake of therapeutic oligonucleotides across multiple target tissues, including skeletal and cardiac muscle as well as the central nervous system, as demonstrated in preclinical studies. The company has multiple EDO-based candidates in development.